Astria Therapeutics Inc. (ATXS), a biopharmaceutical company developing therapies for allergic and immunologic diseases, has a near-term catalyst to watch involving its drug candidate STAR-0310.
STAR-0310 is a monoclonal antibody OX40 antagonist that is in development for the potential treatment of atopic dermatitis (AD). OX40 inhibition is a clinically validated mechanism for the treatment of AD.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.